MEI Pharma price target raised to $7.50 from $6 at Oppenheimer

MEI Pharma price target raised to $7.50 from $6 at Oppenheimer. Oppenheimer analyst Leah Rush raised her price target for MEI Pharma to $7.50 after adjusting her risk discount to reflect the planned registration study for ME-401. The analyst believes the clinical programs are advancing and keeps an Outperform rating on the shares. She anticipates MEI will commercialize its development-stage drug Pracinostat in acute myeloid leukemia and myeloid dysplastic syndromes, and ME-401 in chronic lymphocytic leukemia and follicular lymphoma, in 2022.
https://thefly.com/landingPageNews.php?id=2784543